Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data
Ning Zhao,Maozu Guo,Kuanquan Wang,Chunlong Zhang,Xiaoyan Liu
DOI: https://doi.org/10.3389/fbioe.2020.00268
IF: 5.7
2020-04-02
Frontiers in Bioengineering and Biotechnology
Abstract:Prognostic biomarkers dedicating to treat cancer are very difficult to identify. Although high-throughput sequencing technology allows us to mine prognostic biomarkers much deeper by analyzing omics data, there is lack of effective methods to comprehensively utilize multi-omics data. In this work, we integrated multi-omics data [DNA methylation (DM), gene expression (GE), somatic copy number alternation, and microRNA expression (ME)] and proposed a method to rank genes by desiring a "Score." Applying the method, cancer-specific prognostic biomarkers for 13 cancers were obtained. The prognostic powers of the biomarkers were further assessed by C-indexes (ranged from 0.76 to 0.96). Moreover, by comparing the 13 survival-related gene lists, seven genes (<i>SLK</i>, <i>API5</i>, <i>BTBD2</i>, <i>PTAR1</i>, <i>VPS37A</i>, <i>EIF2B1</i>, and <i>ZRANB1</i>) were found to be associated with prognosis in a variety of cancers. In particular, <i>SLK</i> was more likely to be cancer-related due to its high missense mutation rate and associated with cell adhesion. Furthermore, after network analysis, <i>EPRS</i>, <i>HNRNPA2B1</i>, <i>BPTF</i>, <i>LRRK1</i>, and <i>PUM1</i> were demonstrated to have a broad correlation with cancers. In summary, our method has a better integration of multi-omics data that can be extended to the researches of other diseases. And the prognostic biomarkers had a better prognostic power than previous methods. Our results could provide a reference for translational medicine researchers and clinicians.
multidisciplinary sciences